论文部分内容阅读
目的探究在小儿反复发作哮喘中给予孟鲁司特、匹多莫德联合治疗的临床疗效。方法选取潮州市妇幼保健院2011年6月-2012年12月共134例患儿,按随机数字表分为对照A组44例(单用孟鲁司特治疗),对照B组44例(单用匹多莫德治疗),治疗组46例(联合孟鲁司特、匹多莫德治疗),对比3组患者间临床资料差异性。结果联合组对比其余两组无症状时间长,就医次数少,3组均无不良反应。联合组显效率71.74%,较对照A组高21.74%,较对照B组高19.47%;联合组有效率为95.65%,较对照A组高4.74%,较对照B组高9.29%;以上数据行统计分析提示,P均<0.05。结论联合孟鲁司特、匹多莫德治疗,提高患儿免疫力,强化抗感染效果,最终减少哮喘发生,疗效显著。
Objective To investigate the clinical efficacy of montelukast and pidotimod in the treatment of recurrent asthma in children. METHODS: A total of 134 children with CHD from June 2011 to December 2012 were divided into control group A (44 cases) and monotherapy group B (44 cases) With pidotimod treatment), the treatment group of 46 patients (montelukast, pidotimod treatment), the comparison of clinical data between the three groups of patients. Results Compared with the other two groups, the asymptomatic group showed longer duration and fewer medical visits, and no adverse reactions were found in the three groups. The effective rate of combination group was 71.74%, which was 21.74% higher than that of control group A, 19.47% higher than that of control group B; the effective rate of combined group was 95.65%, which was 4.74% higher than that of control group A and 9.29% higher than that of control group B; Statistical analysis, P <0.05. Conclusion The combination of montelukast and pidotimod can improve the immunity of children and strengthen the anti-infective effect, and ultimately reduce the incidence of asthma.